FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 19:49:47 25/06/2024 BST | ||
| 1.46 EUR | +4.29% |
|
| Current month | -44.70% | ||
| 1 month | -47.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 1.46 | +4.29% |
| 24/06/24 | 1.4 | -11.95% |
| 21/06/24 | 1.59 | +1.27% |
| 20/06/24 | 1.57 | -8.19% |
| 19/06/24 | 1.71 | +3.64% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 07:49 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK17DM |
| ISIN | DE000JK17DM8 |
| Date issued | 23/02/2024 |
| Strike | 522.4 $ |
| Maturity | Unlimited |
| Parity | 33.86 : 1 |
| Emission price | 10.13 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.64 € |
|---|---|
| Lowest since issue | 1.17 € |
| Spread | 0.15 € |
| Spread % | 9.43% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Certificates
- Certificat
